Results 141 to 150 of about 6,463,095 (311)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Comparison of disease free survival in breast cancer molecular subtypes [PDF]

Caspian Journal of Internal Medicine
Background: Breast cancer management depends on molecular subtypes. The aim was to compare disease-free survival (DFS) among the different subgroups. Overall survival (OS) is a secondary endpoint.
Maryam Esmati, Fatemeh Monfaredi, Mohsen Vakili Sadeghi, Mohammad Ranaee, Hossein ghorbani, Sadegh Sedaghat, Hemmat Gholinia   +6 more
doaj  

Forest plot for progression-free survival.

, 2016
Forest plot for progression-free survival.
Lisa Derosa (2605687), Cristian Lolli (3150675), Emanuela Scarpi (382324), Orazio Caffo (3150690), Sunnya Zarif (3150678), Vincenza Conteduca (3150663), Gianmauro Numico (591004), Francesco Massari (295545), Tony Elliott (3150687), Robert J. Jones (3150666), Paolo Fabbri (3150681), Catherine Hanna (3150669), Helen Joyce (3150672), Simon J. Crabb (1923172), Ugo De Giorgi (2605693), Francesca Maines (3150684)   +15 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital

Clinical and Translational Science
Lung cancer continues to be the leading cause of morbidity and mortality associated with malignancies. Identifying prognostic factors is vital for improving survival outcomes.
Gayathri Baburaj, Ananth Pai, Varun Kumar Sudha Gururaj, Satyanarayana Poojari, Mahadev Rao, Karthik S. Udupa   +5 more
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.

, 2016
Progression-free survival according to pre-therapy and follow-up NLR at 4 weeks of enzalutamide treatment.
Lisa Derosa (2605687), Cristian Lolli (3150675), Emanuela Scarpi (382324), Orazio Caffo (3150690), Sunnya Zarif (3150678), Vincenza Conteduca (3150663), Gianmauro Numico (591004), Francesco Massari (295545), Tony Elliott (3150687), Robert J. Jones (3150666), Paolo Fabbri (3150681), Catherine Hanna (3150669), Helen Joyce (3150672), Simon J. Crabb (1923172), Ugo De Giorgi (2605693), Francesca Maines (3150684)   +15 more
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Oncology Reviews
Background:Malignant gliomas are known with poor prognosis and low rate of survival among brain tumors. Resection surgery is followed by chemotherapy and radiotherapy in treatment of gliomas which is known as the conventional treatment.
Elnaz Amanzadeh Jajin, Saeed Oraee Yazdani, Alireza Zali, Abolghasem Esmaeili   +3 more
doaj   +1 more source

Progression Free Survival as per Performance Status.

, 2016
Progression Free Survival as per Performance Status.
Vipul Doshi (3123906), Vijay M Patil (3123912), Subhadha Kane (3123915), Arvind Sahu (3123900), Amit Joshi (404666), Rajiv Kumar (117613), Kumar Prabhash (404662), Anant Ramaswamy (3123918), Vanita Noronha (404661), Abhishek Mahajan (3123903), Lingaraj Nayak (3123909), Amit Janu (3123897), Anuradha Chougule (404664)   +12 more
core   +1 more source